A kind of pharmaceutical composition for treating diabetes

A composition and a technology for diabetes, applied in the field of medicine, can solve the problems of undiscovered sitagliptin and berberine diabetes, etc., and achieve the effects of improving the therapeutic effect, preventing further deterioration and reducing the side effects of drugs

Active Publication Date: 2018-02-02
ZHEJIANG UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, through the search of public publications at home and abroad, no related reports have been found about sitagliptin and berberine or their pharmaceutically acceptable salts as a compound drug for the treatment of diabetes and its complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition for treating diabetes
  • A kind of pharmaceutical composition for treating diabetes
  • A kind of pharmaceutical composition for treating diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] 1. KKAy mice (SPF grade, male, 6-8 weeks), provided by Beijing Huafukang Biotechnology Co., Ltd. All experimental animals were used for experiments after adaptive feeding for 10 days.

[0029] 2. Grouping and handling of animals

[0030] The hyperglycemic KKAy mice were randomly divided into 4 groups, namely the model group, the sitagliptin group, the berberine group and the sitagliptin and berberine composition group. The grouping and administration are shown in Table 1. All mice were intragastrically administered corresponding doses of drugs every day. The mice in the model group were given the same volume of solvent 0.5% sodium carboxymethylcellulose solution (0.05% CMC-Na).

[0031] Table 1 Animal treatment methods in each group

[0032]

drug

Dose (mg / kg)

model group

\

\

sitagliptin group

sitagliptin

50

Berberine group

Berberine Hydrochloride

300

Composition group

Sitagliptin + Berberine Hydroch...

Embodiment 2

[0043] 1. C57BL / 6, KKAy mice (SPF grade, male), provided by Beijing Huafukang Biotechnology Co., Ltd. All experimental animals were used for experiments after adaptive feeding for about 10 days.

[0044] 2. Grouping and handling of animals

[0045] C57BL / 6 mice were used as a control group, and KKAy mice were randomly divided into two groups: model group, sitagliptin and berberine composition group (sitagliptin 20 mg / kg+berberine hydrochloride 300 mg / kg). All mice were intragastrically administered corresponding doses of drugs every day, and mice in the model group were given the same volume of solvent 0.5% sodium carboxymethylcellulose solution (0.05% CMC-Na).

[0046] 3. Determination of random blood glucose and fasting blood glucose

[0047] After the administration, the random blood glucose of the mice was measured once a week, and the specific operation was as follows: after the administration, blood was collected from the tail vein to detect the glucose level. After t...

Embodiment 3

[0050] Sitagliptin and berberine hydrochloride composition tablet preparation

[0051]

[0052] Preparation process: Pass the microcrystalline cellulose and low-substituted methyl cellulose in the prescription through an 80-mesh sieve, weigh the prescribed amount of sitagliptin, berberine hydrochloride, and mix them evenly with microcrystalline cellulose and low-substituted methyl cellulose , add 2% hydroxypropyl methylcellulose solution to granulate in an appropriate amount, dry, granulate, add prescription amount of magnesium stearate, mix evenly, and compress into tablets to obtain 1000 tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating diabetes, which comprises sitagliptin or its pharmaceutically acceptable salt and berberine or its pharmaceutically acceptable salt as active ingredients. The composition can effectively reduce blood sugar level and improve the body's glucose tolerance level, and its effect is significantly better than that of sitagliptin or berberine alone. Under the premise of ensuring the same curative effect, the combined drug can reduce the administration of each drug The dose can enhance the tolerance of long-term medication of diabetic patients and reduce the occurrence of drug side effects. In addition, the combination of medication can not only prevent the further deterioration of the course of diabetes, but also improve the pathological process of diabetes that has occurred.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to a pharmaceutical composition for treating diabetes, in particular to a pharmaceutical composition containing sitagliptin or a pharmaceutically acceptable salt thereof and berberine or a pharmaceutically acceptable salt thereof. Background technique [0002] Diabetes mellitus is a common endocrine and metabolic disease characterized by hyperglycemia. The main pathophysiological changes of diabetes are insulin secretion defect or its biological function is impaired, so that glucose cannot be used normally by the body, causing metabolic disorders of sugar, protein, fat, water and electrolytes in the body. In recent years, with the improvement of people's living standards, changes in lifestyle and population aging, the incidence of diabetes has been increasing. According to the statistics of the International Diabetes Federation (International Diabetes Federation, IDF), there were ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4985A61P3/10A61K31/4375
Inventor 程翼宇范骁辉王毅
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap